| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |